KR20230084499A - 니코틴아미드 내포 미셀, 및 니코틴아미드 내포 미셀을 포함하는 임신 고혈압 증후군 치료용 조성물 - Google Patents

니코틴아미드 내포 미셀, 및 니코틴아미드 내포 미셀을 포함하는 임신 고혈압 증후군 치료용 조성물 Download PDF

Info

Publication number
KR20230084499A
KR20230084499A KR1020237011919A KR20237011919A KR20230084499A KR 20230084499 A KR20230084499 A KR 20230084499A KR 1020237011919 A KR1020237011919 A KR 1020237011919A KR 20237011919 A KR20237011919 A KR 20237011919A KR 20230084499 A KR20230084499 A KR 20230084499A
Authority
KR
South Korea
Prior art keywords
nicotinamide
micelles
block copolymer
micelle
polyether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020237011919A
Other languages
English (en)
Korean (ko)
Inventor
호라시오 카브랄
다쿠야 미야자키
펑원 천
나오야 가와시마
Original Assignee
고쿠리츠다이가쿠호우진 도쿄다이가쿠
아스카 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고쿠리츠다이가쿠호우진 도쿄다이가쿠, 아스카 세이야쿠 가부시키가이샤 filed Critical 고쿠리츠다이가쿠호우진 도쿄다이가쿠
Publication of KR20230084499A publication Critical patent/KR20230084499A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237011919A 2020-10-09 2021-10-08 니코틴아미드 내포 미셀, 및 니코틴아미드 내포 미셀을 포함하는 임신 고혈압 증후군 치료용 조성물 Withdrawn KR20230084499A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020171414 2020-10-09
JPJP-P-2020-171414 2020-10-09
PCT/JP2021/037453 WO2022075470A1 (ja) 2020-10-09 2021-10-08 ニコチンアミド内包ミセル、及びニコチンアミド内包ミセルを含む妊娠高血圧症候群治療用組成物

Publications (1)

Publication Number Publication Date
KR20230084499A true KR20230084499A (ko) 2023-06-13

Family

ID=81126087

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237011919A Withdrawn KR20230084499A (ko) 2020-10-09 2021-10-08 니코틴아미드 내포 미셀, 및 니코틴아미드 내포 미셀을 포함하는 임신 고혈압 증후군 치료용 조성물

Country Status (6)

Country Link
US (1) US20230301909A1 (https=)
EP (1) EP4226925A4 (https=)
JP (1) JPWO2022075470A1 (https=)
KR (1) KR20230084499A (https=)
CN (1) CN116322648A (https=)
WO (1) WO2022075470A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4485805A1 (en) 2023-06-29 2025-01-01 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Analog-to-digital converter

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015030721A (ja) 2013-08-07 2015-02-16 国立大学法人東北大学 ニコチンアミドによる妊娠高血圧症候群、流産・早産、及び子宮内胎児発育遅延の改善

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030466A2 (en) * 2000-10-11 2002-04-18 Purdue Research Foundation Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof
US20090156459A1 (en) * 2007-11-16 2009-06-18 Pharmain Corporation Cationic-Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
CN105801847A (zh) * 2016-03-16 2016-07-27 华东师范大学 一种用于抗肿瘤药物递送的助溶高分子载体及制备方法
CN109568268A (zh) * 2017-09-28 2019-04-05 中国科学院深圳先进技术研究院 胎盘靶向递送系统及其制备方法和应用
US20220257790A1 (en) * 2019-06-26 2022-08-18 Biorchestra Co., Ltd. Micellar nanoparticles and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015030721A (ja) 2013-08-07 2015-02-16 国立大学法人東北大学 ニコチンアミドによる妊娠高血圧症候群、流産・早産、及び子宮内胎児発育遅延の改善

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Diabetologia (2000) vol.43 (11), 1337-45
F. Li et. al., PNAS (2016), vol.113, No.47 13450-13455
H. Cabral et. al., Nat. Nanotech. 6 (2011) 815-823
J. R. Huston et. al., Clin. Pharmacol. Ther. 90 (2011) 67
K. Shintaku et. al., Drug Metab. Dispos. 37 (2009) 962
M. Nagai et. al., Drug Metab. Dispos. 41 (2013) 2124
Macromol. Biosci. (2020) (20) 1900161

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4485805A1 (en) 2023-06-29 2025-01-01 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Analog-to-digital converter

Also Published As

Publication number Publication date
CN116322648A (zh) 2023-06-23
US20230301909A1 (en) 2023-09-28
WO2022075470A1 (ja) 2022-04-14
EP4226925A1 (en) 2023-08-16
JPWO2022075470A1 (https=) 2022-04-14
EP4226925A4 (en) 2025-07-23

Similar Documents

Publication Publication Date Title
EP1971622B1 (en) A biocompatible, non-biodegradable, non-toxic polymer useful for nanoparticle pharmaceutical compositions
JP5037684B2 (ja) ドセタキセル高分子誘導体、並びにその製造方法及びその用途
Wu et al. pH/redox dual-responsive amphiphilic zwitterionic polymers with a precisely controlled structure as anti-cancer drug carriers
Leong et al. Disease-directed design of biodegradable polymers: Reactive oxygen species and pH-responsive micellar nanoparticles for anticancer drug delivery
JP2011137046A (ja) Ｎ，ｏ−アミドマロネート白金錯体
WO2013023003A1 (en) Bioactive amphiphilic polymer stabilized nanoparticles with enhanced stability and activity
EP3106177A1 (en) COMPOSITION FOR mRNA DELIVERY
US20250288605A1 (en) Oxygen reactive polymers for treatment of traumatic brain injury
Zhang et al. Poly (ethylene glycol) shell-sheddable TAT-modified core cross-linked nano-micelles: TAT-enhanced cellular uptake and lysosomal pH-triggered doxorubicin release
JP2010528105A (ja) 癌の診断と治療を同時に遂行する抗癌剤
Wang et al. Polymeric micelles with α-glutamyl-terminated PEG shells show low non-specific protein adsorption and a prolonged in vivo circulation time
KR20230084499A (ko) 니코틴아미드 내포 미셀, 및 니코틴아미드 내포 미셀을 포함하는 임신 고혈압 증후군 치료용 조성물
Nakka et al. Dual drug-loaded tumor-targeted polymeric nanoparticles for enhancing therapeutic response in pancreatic ductal adenocarcinoma
CN102051016B (zh) 可降解的双亲性三嵌段共聚物胶束及其制备方法和用途
Pan et al. Dendron-polymer hybrid mediated anticancer drug delivery for suppression of mammary cancer
Chen et al. Propionate-functionalized chitosan hydrogel nanoparticles for effective oral delivery of insulin
CN107224589B (zh) 一种输送抗体用于肿瘤免疫治疗的mr成像聚合物胶束及其制备方法
WO2006098496A1 (ja) ジアミノシクロヘキサン白金(ii)とブロック共重合体との配位化合物及びそれを含有する抗がん剤
KR101541969B1 (ko) 단백질 전달용 나노 복합체 및 이의 제조방법
JP2011162569A (ja) カンプトテシン高分子誘導体及びその用途
KR101788610B1 (ko) 의약용 단백질의 지속방출을 위한 약물전달체 및 이의 제조방법
CN107337653A (zh) 四碘甲腺原氨酸‑n‑羧基内酸酐、聚四碘甲腺原氨酸及其制备方法与应用
CN114652747B (zh) 一种双前药骨架聚合物PCPt、其纳米颗粒及其制备方法和应用
Ventura-Hunter et al. Amphiphilic block copolymer conjugated with cell-penetrating-peptides derived from Influenza A H1N1 virus as a biocompatible scaffold for enhanced cell-uptake
CN117003820A (zh) 一种基于含巯基的两性离子多肽修饰的可降解两亲性分子、纳米胶束及其制备方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202

WITB Written withdrawal of application